Phase I Deep Brain Stimulation (DBS) vs. Best Medical Therapy (BMT) Trial
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The goals of this study are to determine if simultaneous bilateral subthalamic nucleus stimulation or simultaneous bilateral globus pallidus stimulation is more effective in reducing symptoms of Parkinson's disease, and if deep brain stimulation or best medical therapy is more effective in improving Parkinson's disease symptoms
| Condition | Intervention | Phase |
|---|---|---|
|
Parkinson's Disease |
Procedure: Bilateral Deep Brain Stimulation Other: best medical therapy |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | CSP #468 - A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson's Disease, Phase I |
- time spent in the 'on' state without troubling dyskinesia based on patient motor diaries [ Time Frame: at six months ] [ Designated as safety issue: No ]
- Scores on the UPDRS for motor function 'off' medication and 'on' stimulation. [ Time Frame: at two years ] [ Designated as safety issue: No ]
| Enrollment: | 316 |
| Study Start Date: | April 2002 |
| Study Completion Date: | October 2008 |
| Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Deep Brain Stimulation
|
Procedure: Bilateral Deep Brain Stimulation
The DBS site (STN or GPi) will be assigned on a random basis at the time the patient enters the surgical phase of the trial.
|
|
Active Comparator: 2
Best Medical Therapy
|
Other: best medical therapy
Participants will initially be randomized to DBS or to 6 months of "best medical therapy." BMT participants will then proceed into the surgical phase of the trial. Effective 08/05/05, randomization to the BMT arm has been discontinued since the study has sufficient information to compare the outcomes of DBS and BMT patients at 6 months.
|
Detailed Description:
Deep BrainDeep Brain Stimulation (DBS) is a promising therapy for Parkinson's disease (PD). Whether DBS is superior to comprehensive best medical therapy or whether some patients or symptoms respond better to DBS in one area of the brain or the other is currently not known.
The goals of this project are to compare the effectiveness of DBS and comprehensive medical therapy as treatments for PD, and to compare bilateral DBS at 2 areas of the brain--the subthalamic nucleus (STN) and the globus pallidus (Gpi)--to determine the most effective brain site for surgical intervention
In this prospective, randomized, multi-center trial, 316 patients will be enrolled at 13 centers over four and a half years. Patients will initially be randomized to immediate surgery (DBS) or to 6 months of "best medical therapy." BMT patients will then proceed into the surgical phase of the trial. The DBS site (STN or GPi) will be assigned on a random basis at the time the patient enters the surgical phase of the trial. Patients will be followed for two years post surgery (24-30 months). Effective 08/05/05, randomization to the BMT arm has been discontinued since the study has sufficient information to compare the outcomes of DBS and BMT patients at 6 months. The findings will be critically important in establishing the optimal surgical treatment of the disabling symptoms of PD.
Eligibility| Ages Eligible for Study: | 22 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- idiopathic Parkinson's disease,
- Hoehn and Yahr stage 2 or worse "off" medications,
- L-dopa responsive but with persistent disabling symptoms (i.e., refractory to "best medical treatment" with motor fluctuations, dyskinesias),
- on stable medical therapy for at least one month prior to enrollment,
- age > 21,
- available and willing to be followed-up according to study protocol, and
- no intracranial abnormalities that would contraindicate surgery (based on pre-operative magnetic resonance imaging of the brain).
Exclusion Criteria:
- "Parkinson's plus" syndromes,
- medical contraindications to surgery or stimulation,
- active alcohol or drug abuse,
- score on minimental status exam 24 or lower, or other neuropsychological dysfunction (e.g., dementia) that would contraindicate surgery,
- concurrent participation in another research protocol.
Contacts and Locations| United States, California | |
| University of California at Los Angeles | |
| Los Angeles, California, United States, 90095 | |
| VA Medical Center, San Francisco | |
| San Francisco, California, United States, 94121 | |
| University of California at San Francisco | |
| San Francisco, California, United States, 94143 | |
| VA Greater Los Angeles Healthcare System, West LA | |
| West Los Angeles, California, United States, 90073 | |
| United States, Iowa | |
| VA Medical Center, Iowa City | |
| Iowa City, Iowa, United States, 52246-2208 | |
| United States, Oregon | |
| Oregon Health Sciences University | |
| Portland, Oregon, United States, 97239 | |
| VA Medical Center, Portland | |
| Portland, Oregon, United States, 97201 | |
| United States, Pennsylvania | |
| Pennsylvania Hospital | |
| Philadelphia, Pennsylvania, United States, 19107 | |
| VA Medical Center, Philadelphia | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| United States, Texas | |
| Baylor College of Medicine | |
| Houston, Texas, United States, 77030 | |
| Michael E. DeBakey VA Medical Center (152) | |
| Houston, Texas, United States, 77030 | |
| United States, Virginia | |
| Medical College of Virginia | |
| Richmond, Virginia, United States, 23298 | |
| Hunter Holmes McGuire VA Medical Center | |
| Richmond, Virginia, United States, 23249 | |
| United States, Washington | |
| VA Puget Sound Health Care System, Seattle | |
| Seattle, Washington, United States, 98108 | |
| Study Chair: | Kenneth Follett | VA Medical Center, Iowa City |
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Follett, Kenneth - Study Chair, Department of Veterans Affairs |
| ClinicalTrials.gov Identifier: | NCT00056563 History of Changes |
| Obsolete Identifiers: | NCT00101556 |
| Other Study ID Numbers: | 468 Phase I, VA-NINDS-01 |
| Study First Received: | March 18, 2003 |
| Last Updated: | February 24, 2010 |
| Health Authority: | United States: Federal Government United States: Food and Drug Administration |
Keywords provided by Department of Veterans Affairs:
|
Parkinson's disease levo-dopa tremor |
dyskinesia subthalamic nucleus globus pallidus |
Additional relevant MeSH terms:
|
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases |
ClinicalTrials.gov processed this record on May 19, 2013